-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1696 Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Epidemiology, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Real-world evidence, Aggressive lymphoma, Lymphoid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Nicolò Rampi, MD1*, Alessandro Bosi, MD2*, Michele Merli, MD3*, Maria Goldaniga, MD4*, Stefano Ferrero, MD5,6*, Stefano Fiori, MD5*, Giorgio alberto Croci, MD7*, Francesco Blasi, MD8,9*, Valeria Rossetti, MD9*, Letizia Morlacchi, MD8,9*, Mario Nosotti, MD8,10*, Lorenzo Rosso, MD8,10*, Pietro Lampertico, MD8,11*, Francesca Donato, MD11*, Clara Dibenedetto, MD11*, Lucio Caccamo, MD12*, Barbara Antonelli, MD12*, Maria Campise, MD13*, Mariano Ferraresso, MD14*, Evaldo Favi, MD14,15*, Giorgia Saporiti, MD4*, Fabio Serpenti, MD4*, Kordelia Barbullushi, MD4*, Bruno Fattizzo, MD1,16, Francesca Gaia Rossi, MD17* and Francesco Passamonti, MD18,19*

1Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, Milan, Italy
3Hematology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
4SC Ematologia, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
5Pathology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
6Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
7Pathology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
8Department of Pathophysiology and Transplantation University of Milan, Milan, Italy
9Respiratory Unit and Cystic Fibrosis Center Fondazione IRCCS OCR Granda Ospedale Maggiore Policlinico, Milan, Italy
10Thoracic Surgery and Lung Transplantation Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
11Gastroenterology and Hepatology Unit,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Milan, Italy
12General Surgery and Liver Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
13SC Nephrology, Dialysis and Kidney Transplantation Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy
14General Surgery and Kidney Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
15Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
16Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy
17Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
18Università degli Studi di Milano, Milano, Italy
19Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano, Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca Granda, Milano, Italy

Background: Post-transplant lymphoproliferative disorder (PTLD) is a rare and potentially life-threatening complication of solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (HSCT), affecting up to 10-20% of recipients. Prognosis is highly variable, and several prognostic factors have been identified. Real-life experience is needed to better understand this rare entity.

Methods: We retrospectively collected data on all PTLD cases following SOT and HSCT diagnosed at Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, between 2007 and 2023. All patients were ≥18 years old at the time of diagnosis, with diagnosis of destructive PTLD occurrence from 2007 to 2023, and received active treatment for PTLD.

Results: A total of 46 PTLD patients (pts) were included: 8 (17%) after lung, 19 (41%) after liver, 16 (35%) after kidney transplant (Tx), and 3 (7%) after HSCT. Within a cohort of 2171 transplanted pts, the incidence of PTLD was 0.17 per 100 patient-years for kidney, 0.18 for lung, 0.22 for liver, and 0.07 for bone marrow tx. The median age at PTLD diagnosis was 47 years (range 18-79), with 35 (76%) having advanced-stage disease, 13 out of 43 (30%) with an ECOG score ≥ 2, and 15 out of 43 (35%) presenting with B symptoms. Increased LDH levels were observed in 26 out of 37 (70%) cases. PTLD-IPI scores of 2-3 were found in 17 out of 37 (46%) cases. Histologically, DLBCL was the most common subtype (78%) and 3 (7%) polymorphic PTLD.

The median time from Tx to PTLD diagnosis was 64 months (mos) (range 2-378) in the overall population, varying from 3 (range 2-56) for lungs to 111 mos (range 2-241) for kidneys. Twelve (26%) cases occurred within the first year (early-onset) after Tx. EBV positivity was detected in 17 out of 39 (43%) pts with available information, with the highest rates in lung Tx (75%) and HSCT (100%).

At diagnosis, pts were receiving a median of 2 immunosuppressants (IS) (range 0-3): 21 (47%) were receiving prednisone, 45 (98%) a calcineurin inhibitor, and 21 (47%) mofetil mycophenolate.

IS were reduced in all pts, with 2 pts requiring no further therapy. Nine (20%) pts received single-agent rituximab, all of whom experienced progressive disease. Two pts were treated with RIS and concomitant excisional surgery. Chemo/chemo-immunotherapy was administered to 42 (91%) pts (upfront in 37 pts due to disease burden). The overall response rate was 70%, with a complete response (CR) in 55%. No graft rejection was reported.

With a median follow-up of 20 mos (1-161), 22 (48%) pts relapsed or progressed, with a median progression-free survival of 25 mos (1-161). At the time of analysis, 22 (48%) pts had died (82% from lymphoma): 4 lung, 10 liver, 9 kidney and no HSCT Tx pts were alive. The median overall survival (OS) was 66 mos (1-161). Higher mortality rates were associated with PTLDs after HSCT (HR 10, 95% CI 2.7-42.5) and after lung Tx (HR 15, 95% CI 0.5-4.5), with a median OS of 2 mos (1-8) and 22 months (1-104), respectively. Increased LDH (HR 7.3, 95% CI 1.7-31.8), ECOG ≥ 2 (HR 4.5, 95% CI 1.9-10.8), B symptoms (HR 3.5, 95% CI 1.4-8.3), early-onset PTLD (HR 3.1, 95% CI 1.2-7.5), and single-agent rituximab treatment (HR 2.6, 95% CI 0.9-6.8) were significantly associated with worse survival. PTLD-IPI was a strong predictor of OS (HR 2.5, 95% CI 1.4-4.5). At multivariate analysis, only increased LDH, EBV positivity, and age >60 years maintained a prognostic role.

Conclusions: We found that HSCT and lung Tx were more frequently EBV positive, of early-onset and associated with worse prognosis. Beside age and LDH, EBV positivity emerged as significant prognostic factor.

Disclosures: Fattizzo: Zenas BioPharma: Research Funding; Agios: Research Funding; Sobi: Speakers Bureau; Samsung: Speakers Bureau; Novartis: Consultancy; Roche: Consultancy, Other: travel to congress; Alexion: Consultancy; Janssen: Consultancy. Rossi: Incyte: Membership on an entity's Board of Directors or advisory committees; Jansen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees. Passamonti: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH